References
- Primrose JN, Fox RP, Palmer DH, et al. Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study. J Clin Oncol. 2017;35(Suppl 15):4006.
- Oh D-Y, He AR, Qin S, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694-704.
- Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853–1865.
- Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(12):1015-1027.
- Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28–v37.
- Neeva A, Grigorov E, Salchev P. Opportunities and challenges in the implementation of the 11th revision of the international classification of diseases in Bulgaria. General Medicine. 2025;27(3):28–36.
- EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023;79(1):181-208.
- The International Agency for Research on Cancer (IARC). Global Cancer Observatory [Internet]. Available from: https://gco.iarc.fr/en
- Petrova G, Kostadinova T, Georgieva E. Possible benefits for the health system of the implementation of integrated care. Journal of IMAB – Annual Proceeding (Scientific Papers). 2015;21(3):833-836.